What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.

Original reporting
Published Nov 3, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 7:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Sotera Health (SHC) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$SHCNeutralMed
01

Why it matters

Near-term segment growth expectations were adjusted lower for Q4 (Sterigenics sequential growth) and Nordion revenue declined due to cobalt-60 harvest timing, but management reaffirmed full-year 2026 guidance and highlighted margin/leverage improvements.

02

Market read

Traders can update Q4 expectations for Sterigenics and Nordion based on management’s directional commentary, while using reaffirmed 2026 guidance and leverage improvement to frame downside risk.

03

What to watch

Margin improvement at Nordion and improved net leverage (2.9x) could be underweighted versus the revenue decline; also, Sterigenics capacity and ethylene oxide upgrades may support later-year normalization.

Relevance 7/10Novelty 6/10Timing: post-Q3 earnings call, informs positioning for Q4 and 2027 capex planning

Background

The piece summarizes Sotera Health’s Q3 earnings call, including segment demand commentary, Nordion shipment timing, cash flow/leverage, and litigation scheduling.

Company-level read

Ticker impact

$SHCNeutralMedium confidence
Context

Sotera Health guided 2026 revenue and EBITDA while updating Q4 growth expectations for Sterigenics and Nordion shipment timing.

Expected impact

Likely modest downside bias as investors weigh weaker sequential Sterigenics growth and Nordion revenue decline against reaffirmed full-year targets and improved margins.

Evidence & confidence

The article provides specific Q4 directional commentary (Sterigenics not expecting normal sequential growth, Nordion revenue down on shipment timing) plus reaffirmed full-year guidance and leverage improvement, which should temper but not eliminate near-term concerns.

Market effects

Sterilization and radiopharma-adjacent services demand signals, especially Europe medical-device softness, may influence peers’ near-term demand expectations.

Europe customer softness is highlighted as the driver, suggesting regional demand divergence versus the U.S.

Shipment-timing dynamics in cobalt-60 harvest schedules underscore operational variability that can affect broader supply-chain expectations.

Counterpoint

Reaffirmed 2026 constant-currency revenue and adjusted EBITDA guidance suggests the softness may be more timing-related than structural, limiting downside beyond Q4.

Key entities

  • Sotera Health

    NASDAQ-listed sterilization and laboratory testing provider, subject of the earnings-call update.

  • Sterigenics

    Outsourced sterilization segment referenced for Q4 sequential growth expectations.

  • Nelson Labs

    Laboratory testing segment with revenue growth and margin commentary.

  • Nordion

    Cobalt-60-related revenue and margin performance discussed, including shipment timing effects.

  • Moody’s

    Upgraded Sotera Health’s credit rating in early October, supporting leverage narrative.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.